S. Pezzulli

878 total citations
19 papers, 704 citations indexed

About

S. Pezzulli is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, S. Pezzulli has authored 19 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in S. Pezzulli's work include Cancer, Hypoxia, and Metabolism (8 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer Treatment and Pharmacology (5 papers). S. Pezzulli is often cited by papers focused on Cancer, Hypoxia, and Metabolism (8 papers), Cancer therapeutics and mechanisms (6 papers) and Cancer Treatment and Pharmacology (5 papers). S. Pezzulli collaborates with scholars based in United States, Slovakia and Canada. S. Pezzulli's co-authors include David R. Spriggs, Paul Sabbatini, Carol Aghajanian, Martee L. Hensley, Steven L. Soignet, Don S. Dizon, Christine Pien, Vincent A. Miller, Adil Daud and Julian Adams and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

S. Pezzulli

19 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Pezzulli United States	10	403	352	142	104	94	19	704
Nicoletta Staropoli Italy	14	233 0.6×	350 1.0×	74 0.5×	80 0.8×	112 1.2×	42	617
Lee Wisner United States	8	216 0.5×	194 0.6×	61 0.4×	117 1.1×	88 0.9×	21	544
Olga Camacho‐Vanegas United States	16	564 1.4×	127 0.4×	92 0.6×	37 0.4×	114 1.2×	25	862
Lindsey Rolfe United States	12	374 0.9×	622 1.8×	36 0.3×	78 0.8×	199 2.1×	30	856
Cristina Nieto‐Jiménez Spain	16	456 1.1×	464 1.3×	84 0.6×	181 1.7×	139 1.5×	40	942
Caner Saygin United States	10	426 1.1×	337 1.0×	156 1.1×	79 0.8×	66 0.7×	27	767
Robert H. Gersh United States	7	190 0.5×	151 0.4×	206 1.5×	37 0.4×	35 0.4×	8	501
Katarina Luptakova United States	14	521 1.3×	698 2.0×	460 3.2×	183 1.8×	44 0.5×	50	1.1k
Ines A. Silva United States	4	258 0.6×	355 1.0×	47 0.3×	121 1.2×	29 0.3×	6	536
Jennifer A. Grabowsky United States	12	389 1.0×	274 0.8×	25 0.2×	67 0.6×	104 1.1×	29	634

Countries citing papers authored by S. Pezzulli

Since Specialization

Citations

This map shows the geographic impact of S. Pezzulli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Pezzulli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Pezzulli more than expected).

Fields of papers citing papers by S. Pezzulli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Pezzulli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Pezzulli. The network helps show where S. Pezzulli may publish in the future.

Co-authorship network of co-authors of S. Pezzulli

This figure shows the co-authorship network connecting the top 25 collaborators of S. Pezzulli. A scholar is included among the top collaborators of S. Pezzulli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Pezzulli. S. Pezzulli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Konner, Jason, Scott R. Gerst, Alexia Iasonos, et al.. (2011). Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer. Journal of Clinical Oncology. 29(35). 4662–4668. 44 indexed citations

2.

Tew, William P., Michael S. Gordon, John R. Murren, et al.. (2009). Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(1). 358–366. 62 indexed citations

3.

Konner, Jason, S. Pezzulli, Alexia Iasonos, et al.. (2009). A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Journal of Clinical Oncology. 27(15_suppl). 5539–5539. 4 indexed citations

4.

Dizon, Don S., Fernando Cotait Maluf, Carol Aghajanian, et al.. (2008). Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies. Journal of Clinical Oncology. 26(15_suppl). 2568–2568. 2 indexed citations

5.

Diefenbach, Catherine, Sacha Gnjatic, Paul Sabbatini, et al.. (2008). Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research. 14(9). 2740–2748. 85 indexed citations

6.

Juretzka, Margrit M., Carol Aghajanian, Martee L. Hensley, et al.. (2007). Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers. Journal of Clinical Oncology. 25(18_suppl). 5564–5564. 5 indexed citations

7.

Maluf, Fernando Cotait, Aliza Leiser, Carol Aghajanian, et al.. (2006). Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. International Journal of Gynecological Cancer. 16(3). 1165–1171. 27 indexed citations

8.

Maluf, Fernando Cotait, Aliza Leiser, Paul Sabbatini, et al.. (2006). Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. International Journal of Gynecological Cancer. 16(3). 1165–1171. 8 indexed citations

9.

Aghajanian, Carol, Paul Sabbatini, Scott R. Gerst, et al.. (2005). A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. Journal of Clinical Oncology. 23(16_suppl). 5047–5047. 19 indexed citations

10.

Anderson, Shannon W., Don S. Dizon, Paul Sabbatini, et al.. (2004). Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies. Journal of Clinical Oncology. 22(14_suppl). 2098–2098. 9 indexed citations

11.

Springett, Gregory M., Chris H. Takimoto, M. McNamara, et al.. (2004). Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 3127–3127. 17 indexed citations

12.

Springett, Gregory M., Chris H. Takimoto, M. McNamara, et al.. (2004). Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 3127–3127. 10 indexed citations

13.

Dupont, Jakob, Carol Aghajanian, S. Pezzulli, et al.. (2004). Phase I and Pharmacokinetic Study of the Novel Oral Cell-Cycle Inhibitor Ro 31-7453 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 22(16). 3366–3374. 12 indexed citations

14.

Takimoto, Chris H., S. Syed, M. McNamara, et al.. (2004). 504 Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. European Journal of Cancer Supplements. 2(8). 154–154. 1 indexed citations

15.

McNamara, M., J. H. Doroshow, Jakob Dupont, et al.. (2004). Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 2073–2073. 3 indexed citations

16.

McNamara, M., James H. Doroshow, Jakob Dupont, et al.. (2004). Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 2073–2073. 4 indexed citations

17.

Spriggs, David R., Jakob Dupont, S. Pezzulli, et al.. (2003). 547 KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients (Pts) with advanced malignancies. European Journal of Cancer Supplements. 1(5). S165–S166. 17 indexed citations

18.

Aghajanian, Carol, Steven L. Soignet, Don S. Dizon, et al.. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.. PubMed. 8(8). 2505–11. 372 indexed citations

19.

Dizon, Don S., Fernando Cotait Maluf, Carol Aghajanian, et al.. (2001). Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies. European Journal of Cancer. 37. S77–S77. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact